4dmedical Ltd. · ASX:4DX
4dmedical — Investor Presentation (February 2024)
36 slides from 4dmedical's investor presentation, Feb 28, 2024
Slide 1: The future of lung health
The future of lung health 4DMedical Limited (ASX:4DX) Investor Presentation: H1 FY2024 February 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activities current as of 28
Slide 3: Agenda
Agenda 1. 1H2024 Highlights 2. Imbio acquisition update 3. 4DMedical commercial update 4. Imbio overview 5. Financials 6. Management 7. Summary 3
Slide 4: 1H2024 - material progress on strategy of 'owning the lung'
1H2024 - material progress on strategy of ‘owning the lung’ ➢ Focus on structure of lung - complementary product offering Acquisition of Imbio ➢ Commercial synergies, including licensing & product extension, and expanded opportunity with the VA ➢ Strong product pipeline ➢ Agree to work collectively
Slide 5: Imbio acquisition drives transformational change in revenue
Imbio acquisition drives transformational change in revenue Operating revenue +63% on a reported basis, +32% on half year proforma basis including Imbio Revenue (AUD $’000) 32% 3,200 3,069 • Imbio acquisition transformational in 3,000 nature, with immediate impact in 2,800 revenue generation. 2,600
Slide 6: Imbio acquisition update
Imbio acquisition update “A Call, al 2 my Uf 2X 4DMedical ..:
Slide 7: Strategic rationale
Strategic rationale Investment thesis proving sound post acquisition, with initial wins in existing contracts and commercial synergies Investment thesis Post Acquisition update Significant growth • Additional 5 lung diagnostic products, resulting in a full suite of • Olympus SeleCT Screening product
Slide 8: Post acquisition wins
Post acquisition wins Combination of 4DMedical and Imbio showing considerable momentum in 2024 1 ➢ Blackford Platform allows multiple imaging applications and AI algorithms to be quickly deployed by institutions Signing of ➢ Blackford acquired by Bayer in 2022 and has since become a leading white-la
Slide 9: Imbio acquisition creates a comprehensive product portfolio
Imbio acquisition creates a comprehensive product portfolio 4 new products in clinical use, with strong product pipeline Strong combined 4DMedical + Imbio: 4 new Imbio FDA approved Access to new markets 4DMedical + Imbio Comprehensive product products and customers product pipeline offering for lung
Slide 10: Growth opportunity: Solving the clinical conundrum for doctors
Growth opportunity: Solving the clinical conundrum for doctors across multiple care areas Clinical conundrum in lung assessment Clinical tools needed to solve the conundrum Applications for technologies in clinical practice ➢ A mismatch between clinical tests and Unexplained Dyspnoea (shortness of i
Slide 11: Growth opportunity: Extending patient recruitment in multiple care areas
Growth opportunity: Extending patient recruitment in multiple care areas Prior CT Scan in hospital COPD Assessment of cohort Drill down to triage Heart Disease Patient diagnosis and Lung Cancer database with Imbio algorithm appropriate care treatment accelerated COPD: #4 cause of death in the U.S.1,
Slide 12: Commercial update
Commercial update
Slide 13: Philips and VA opportunity
Philips and VA opportunity Combined capabilities to build a compelling offer for ‘owning the lung’ and shared purpose Why Philips partner with 4DMedical Veterans Affairs opportunity Progress to date Objectives for 2024 – the rationale ➢ VA opportunity significant and ➢ 4DMedical well positioned to ➢
Slide 14: US reimbursement approved – XV LVAS
US reimbursement approved – XV LVAS® We addressed three key components … and engaged stakeholders across … which paved the way to U.S of reimbursement ... multiple bodies ... reimbursement • American Medical Association CPT Panel and 1 Code – describing the procedure Advisors ✓ Cat III CPT Code1 • R
Slide 15: AU Progress
AU Progress Considerable progress made in refining deployment model and building network Progress in 1H 2024 Focus for 2024 ➢ Expanded network: ➢ Conversion of trial at Ballarat into commercial contract at Integral Diagnostics • Successfully launched pilot with Integral Diagnostics ➢ Expansion of re
Slide 16: Imbio overview
Imbio overview segses_ all, Sa 4X 4DMedical
Slide 17: AI solutions that span lung and heart conditions
AI solutions that span lung and heart conditions affecting 1 in every 5 adults Lung Density Aortic Aneurysm Analysis Incl. patented VDM COPD, Asthma, FDA - TBD CE - TBD Pneumonia, BOS FDA CE Lung Texture Analysis CAC Scoring ILA’s, ILD/IPF CAD/Heart Disease drug-induced fibrosis FDA CE 2023 FDA 2024
Slide 18: Imbio today
Imbio today Two major channels for ‘Go-to-market’ • Partnerships to grow therapeutic franchises through imaging-based Companion screening & qualification of patients • Recognised leader in Lung & Diagnostics • Business model: per-patient or per-site fees paid by device/pharma Cardiothoracic imaging
Slide 19: Companion Diagnostics (CDx)
Companion Diagnostics (CDx) Why Pharma and Med Device companies needs Imaging AI Companion imaging can grow device & pharma businesses by impacting clinical decisions across the entire course of patient care. SCREENING DIAGNOSIS PLANNING TREATMENT FOLLOW-UP Patient A Patient B 45% 40% 15% Find more
Slide 20: CDx example: endobronchial valves (EBVs)
CDx example: endobronchial valves (EBVs) Successfully implemented product offering Opportunity Imbio partnership with Olympus Medical ➢ Endobronchial valves are a new treatment for • Currently servicing 100+ pulmonology practices in severe emphysema (late-stage COPD) the U.S., Europe, Australia and
Slide 21: CDx – SeleCT cohort recruitment triage
CDx – SeleCT cohort recruitment triage Opportunity to identify patients eligible for Bronchoscopic Lung Volume Reduction (BLVR) using SeleCT program ➢ New product feature for Companion Dx that enables patients by to be identified for treatment across an entire health system What is SeleCT? ➢ Enables
Slide 22: Broader application of cohort recruitment
Broader application of cohort recruitment Lung health screening will assist in identification multiple diseases previously undetected Imbio Full Dx CLINICS COPD/ Radiology/PACS Emphysema Algorithms run as patients undergo chest CTs All chest CT’s Navigator & ILD/ Clinician reports Fibrosis Imbio coh
Slide 23: Imbio products
Imbio products aX 4DMedical
Slide 24: Imbio Technology sophisticated and scalable
Imbio Technology sophisticated and scalable Clinical Algorithms – core products Imaging Platform INSPIRATION ANALYSIS (LDAi) Physician Portal + Patient Navigation for rapid detection & diagnosis of emphysema • Fully-automated assessment of areas of low attenuation (LAA, indicative of emphysema) and
Slide 25: Imbio LDA
Imbio LDA Provides a complete picture of COPD and other density-evident conditions AIR TRAPPING ANALYSIS (LDAf) for a complete picture of COPD, and other density-evident conditions • Also known as PRM (Parametric Response Mapping) from the University of Michigan, patented technology in the U.S. and
Slide 26: Imbio LDAf quantification
Imbio LDAf quantification Physician summary report provides actionable insights Physician summary report 1. Key slice visuals 2. Overall % normal lung vs. air trapping & emphysema 3. Detailed data by lobe 1 4. Lung volumes - inspiratory & expiratory 2 3 4 Normal Functional LAA (air-trapping) Persist
Slide 27: Imbio LDAi quantification
Imbio LDAi quantification Simple screening for emphysema (LAA), potential fibrosis or pneumonia (HAA) Physician summary report 1. 3D visuals – derived from single inspiratory phase CT 2. Quick-read summary graph 1 3. Lung Volumes – total lung & lobar 4. LAA & HAA Density % - total lung & lobar 2 3 2
Slide 28: Imbio CAC Analysis
Imbio CAC Analysis Imbio CAC is an FDA-cleared, fully-automated AI solution that detects, visualizes, and quantifies coronary artery calcification from a qualifying chest CT scan • CAC quantifies Agatston score, lesion volume, and lesion mass in total and for each coronary artery. • CAC provides vis
Slide 29: Imbio CAC Analysis
Imbio CAC Analysis Fully automated screening and risk stratification for Coronary Artery Disease CT scan Physician summary report 1. Patient and acquisition information 2. Main Analysis Results: 1 1. Total Agatston score and Arterial Age 2 3 2. Artery detail: # of lesions, Agatston Score (AS), lesio
Slide 30: Financial update
Financial update aX 4DMedical
Slide 31: Income statement
Income statement Operating revenue up 63%; underlying operating costs down 5.4%, net operating expenditure down 14.5% $ Var % Var AUD $'000 1H2024 1H2023 fav/(unfav) fav/(unfav) ➢ Operating revenue of $793k up 63% compared to prior corresponding period (“pcp”). Operating Revenue 793 486 307 63.1% Co
Slide 32: Management
Management cal A ee eS 4X 4DMedical
Slide 33: Executive team
Executive team Accelerating 4DMedical’s patient outcomes and commercialisation Dr ANDREAS FOURAS PhD RACHAEL TENKATEN Dr AIDAN JAMISON PhD DAVID HANNES Managing Director and CEO Chief of Staff Senior Vice President Engineering CEO Imbio Award-winning aerospace engineer and innovator Aerospace engine
Slide 34: Board of Directors Clinical advisors
Board of Directors Clinical advisors Significant medical and commercial sector experience Dr SAM HUPERT MBBS Advisory Board Member Co-founder and Chief Executive Officer of Pro Medicus Ltd (ASX:PME) which develops and markets health imaging software primarily for radiologists in the U.S., Europe and
Slide 35: Summary – transformational acquisition delivering
Summary – transformational acquisition delivering ➢ Imbio acquisition transformational for 4DMedcial at multiple levels: • Immediate revenue generation from established long-term contracts at high gross margin • A comprehensive product portfolio combines function with structure for a compelling offe
Slide 36: 4DMedical Limited (ASX:4DX)
4DMedical Limited (ASX:4DX) Investor Presentation February 2024 Copyright ©4DMedical Limited 2023 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831